ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Liraglutide Alleviates Diabetic Atherosclerosis through Regulating Calcification of Vascular Smooth Muscle Cells

Shi, Li-Li; Hao, Ming; Jin, Zhou-Yun; Peng, Gui-Fang; Tang, Ying-Ying*; Kuang, Hong-Yu*哈尔滨医科大学; 1
DISEASE MARKERS2022-4-25DOI: 10.1155/2022/5013622
5被引8阅读
引用收藏
分享

摘要

Background. Diabetes mellitus (DM) is a group of metabolic diseases characterized by hyperglycemia, which can induce the development of atherosclerosis (AS). Calcification of vascular smooth muscle cells (VSMCs) exerts an important role in the process of AS. In this study, the effects of liraglutide (LIRA) on VSMC under high-glucose condition and its mechanism were explored. Method. After VSMC was treated by high glucose with or without LIRA in vitro, the alkaline phosphatase (ALP) activity was measured by the detection kit, osteogenic marker protein expression was detected by Western blotting, and calcification was determined by alizarin red staining. Subsequently, the DM rat model was established and the ALP activity, calcification, and osteogenic marker proteins were determined in vivo. Immunohistochemical (IHC) staining and hematoxylin-eosin staining were performed on the thoracic aorta of DM rats. Result. The positive rate of SM alpha-actin expression in the DM+AS group was significantly lower than that in control rats, but LIRA administration increased the positive rate in the model. The expression of Cbf alpha-1 and OPN in the DM+AS group was significantly higher than that in the control group, while it was decreased after treatment of LIRA. The ALP activity and calcium content were increased in DM+AS rats, and the treatment of LIRA decreased the phenotypes in the rats, so as to delay the progression of AS in DM rats. Meanwhile, LIRA inhibited the ALP activity, upregulated SM-alpha expression, and downregulated expression of OPN and Cbf alpha-1 in VSMC under high-glucose (HG) conditions. Mechanically, HG-enhanced ALP activity, AKT, and ERK phosphorylation were inhibited by LIRA, PI3K antagonist LY294002, or ERK1/2 antagonist PD98059, in which cotreatment of LIRA with LY294002 and PD98059 could further enhance the effect of LIRA on VSMC, and GLP-1R antagonists reversed the phenotypes in the model. LIRA blocked the osteogenic transformation of VSMC through PI3K and ERK1/2 signaling pathways, which can be reversed by GLP-1R antagonists. Conclusion. LIRA inhibited the abnormalities in VSMC calcification mediated by the GLP-1R, which was related to PI3K/Akt and ERK1/2 MAPK pathways. Therefore, the prospect and significance of LIRA in the treatment of DM complicated with AS were clarified.

学科与关键词

关键词
PROTEIN-KINASEMELLITUSAGONISTSOBESITY
相关
加载中…
  • A novel protective role of lipoxin in inhibiting diabetic vascular calcification via YAP signalling: Health prevention and regulation
    Han, Baihe; Yang, Mengyue; Liu, Qi; Wang, Gang; Ma, Xiaoxue; Hou, Jingbo*; Yu, Bo*Preventive Medicine, 2023, 173: 107556.
  • Glucagon-like peptide-1 attenuates diabetes-associated osteoporosis in ZDF rat, possibly through the RAGE pathway
    Cheng, Yanzhen; Liu, Peng; Xiang, Qianru; Liang, Jiamin; Chen, Huafeng; Zhang, Hua*; Yang, Li*BMC MUSCULOSKELETAL DISORDERS, 2022, 23(1): 465.被引 4
  • AGEs调控RAGE促进人股动脉平滑肌细胞钙化
    何虎强*硕士, 泸州医学院, 2013-04-01.
查看全部 →

发表信息

论文状态
公开发表
期刊
DISEASE MARKERS
发表日期
2022-04-25
卷期
第 2022 卷
页码
5013622
DOI
10.1155/2022/5013622
语言
ENGLISH
期刊等级
4区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81900760]; Natural Science Foundation of Heilongjiang Province [LH2019H084]; Heilongjiang Postdoctoral Research Starting Fund [LBH-Q19120]

作者

  • S

    Shi, Li-Li (第一作者)

    1 · harbin med univ

  • H

    Hao, Ming

    1 · harbin med univ

查看全部 6 位作者收起作者
  • J

    Jin, Zhou-Yun

    1 · harbin med univ

  • P

    Peng, Gui-Fang

    1 · harbin med univ

  • T

    Tang, Ying-Ying (通讯)

    heilongjiang prov hosp

  • K

    Kuang, Hong-Yu (通讯)

    1 · harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417